title: Prostate cancer: ADT after radical prostatectomy - when and how?
authors.forename: Louise
authors.initials: L
authors.lastname: Stone
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage*; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D006801:Humans; D007610:Kallikreins / Q000097:blood; D008297:Male; D011182:Postoperative Care / Q000379:methods* / Q000401:mortality / Q000639:trends*; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000401:mortality / Q000639:trends*; D011471:Prostatic Neoplasms / Q000097:blood / Q000401:mortality / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D015996:Survival Rate / Q000639:trends
chemical_list: D000726:Androgen Antagonists; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen